Maria Cecilia Hospital, GVM Care & Research, Via Corriera, 1, Cotignola 48033, Ravenna, Italy.
Dipartimento di MedicinaTraslazionale, Università del Piemonte Orientale, Via Paolo Solaroli, 17, 28100 Novara, Italy.
Interv Cardiol Clin. 2024 Oct;13(4):483-491. doi: 10.1016/j.iccl.2024.06.003. Epub 2024 Aug 3.
Percutaneous coronary and structural heart interventions are increasingly preferred over cardiac surgery due to reduced rates of periprocedural complications and faster recovery but often require postprocedural antithrombotic therapy for the prevention of local thrombotic events. Antithrombotic therapy is inevitably associated with increased bleeding, the extent of which is proportional to the number, duration, and potency of the antithrombotic agents used. Bleeding complications have important clinical implications, which may outweigh the expected benefit of reducing thrombotic events. Herein, we provide a comprehensive description of the classification and clinical relevance of high bleeding risk in patients undergoing coronary and structural heart interventions.
经皮冠状动脉和结构性心脏病介入治疗因其围手术期并发症发生率较低和恢复较快而越来越受到青睐，但其术后通常需要抗血栓治疗来预防局部血栓事件。抗血栓治疗不可避免地会增加出血风险，其程度与使用的抗血栓药物的数量、持续时间和效力成正比。出血并发症具有重要的临床意义，其可能超过减少血栓事件的预期获益。在此，我们全面描述了接受冠状动脉和结构性心脏病介入治疗的患者的高出血风险的分类和临床相关性。
